The cardiovascular safety of rosiglitazone

@article{Ajjan2008TheCS,
  title={The cardiovascular safety of rosiglitazone},
  author={Ramzi A. Ajjan and Peter J Grant},
  journal={Expert Opinion on Drug Safety},
  year={2008},
  volume={7},
  pages={367 - 376}
}
Background: Thiazolidinediones (rosiglitazone, pioglitazone) influence insulin sensitivity and are used for the treatment of Type 2 diabetes. Rosiglitazone achieves sustained improvements in glycaemic control, whilst having pleiotropic effects on cardiovascular risk factors. However, analysis of cardiovascular outcomes has been controversial. Objectives: Review the cardiovascular safety of rosiglitazone by conducting a literature search. Methods: We conducted a PubMed search and critically… 
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
TLDR
There is a need for rigorous evaluations of new therapeutic approaches in both primary and secondary prevention of stroke and management of acute stroke in patients with type 2 diabetes, and potential strategies for improving outcomes are highlighted.
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
TLDR
The addition of rosiglitazone seemed to confer greater benefits in ghrelin, hs-CRP, systolic blood pressure, and HOMA-IR regulation than metformin monotherapy.
Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone.
TLDR
These results support serum cTnI concentrations as an early biomarker of cardiac liability in rats administered rosiglitazone and support reported cardiac events in patients chronically dosed with PPARγ agonists.
Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial.
TLDR
In a subset of diabetic men from the VADT, intensive glucose management did not affect conventional lipids or ADLS, but had some beneficial effects on particle characteristics as defined by NMR and on ApoCIII.
A Review on Diabetes and Its Management
The current approach to the treatment of both type 1 and type 2 diabetes is to achieve the best possible glucose control. Past clinical trials have shown that glycemia plays a key role in the
Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes.
TLDR
Enrichment of transcripts involved in cardiac muscle cell differentiation and the extracellular matrix provides a panel of biomarkers for further analysis in the context of adverse cardiac outcomes in humans.
Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
TLDR
It is demonstrated that the pharmacological inhibition ofSCD1 translates into improved lipid and glucose metabolic profiles and raises the interest of SCD1 inhibitors as potential new drugs for the treatment of insulin resistance.
Insulin and Other Antidiabetic Agents
TLDR
Diabetes mellitus is a pathologic condition characterized by chronic hyperglycemia (elevated blood glucose) and additional disturbances of carbohydrate, fat, and protein metabolism and the search for insulin in an oral form is discussed.
Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment.
TLDR
The ability of skeletal muscle cells to produce adiponectin, which can mediate autocrine metabolic effects, is shown, thus establishing adip onectin as a bona fide myokine.
A Survey on Prescription Pattern of Diabetes Mellitus
Now a days, diabetes is well known diseases in all parts of the world. About 386 million people is suffered by type 2 diabetes and in 90% cases it is done. Within 2035 year this level will be raised
...
1
2
3
...

References

SHOWING 1-10 OF 72 REFERENCES
The cardiovascular effects of the thiazolidinediones: a review of the clinical data.
TLDR
Because of the unique mechanism of action of this drug class that addresses a fundamental pathophysiolgical phenomenon in type 2 diabetes, namely, improving insulin resistance, and the growing body of evidence supporting cardiovascular benefits, strong consideration should be given to utilizing the TZDs early in the clinical course of diabetes.
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
TLDR
Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol
TLDR
The RECORD study should provide robust data on the extent to which rosiglitazone, in combination with metformin or sulphonylurea therapy, affects CV outcomes and progression of diabetes in the long term.
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
TLDR
Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure, without a significantlyIncreased risk of cardiovascular mortality.
Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
TLDR
A meta-analysis of 42 clinical trials involving 27847 patients concluded that treatment with rosiglitazone, a widely prescribed, peroxisome proliferator-activated receptor- agonist, was associated with an approximately 43% greater risk for myocardial infarction and an approximately 64% greaterrisk for cardiovascular death than placebo or other antidiabetic regimens.
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
TLDR
The interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes.
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
TLDR
Thiazolidinediones have similar effects on glycemic control and body weight and head-to-head comparative trials as well as longer-term cardiovascular outcome studies are needed to determine whether there are differences in efficacy between the 2 thiazolidinees.
Thiazolidinediones and Blood Lipids in Type 2 Diabetes
TLDR
Analysis of double-blind, placebo-controlled studies with RSG and PIO in patients with type 2 diabetes found that subjects treated with PIO were more obese and showed more pronounced hyperglycemia and dyslipidemia, while studies conducted with P IO showed more beneficial effects on blood lipids.
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.
TLDR
Investigation of the cardiac safety and antihyperglycemic effect of rosiglitazone in patients with type 2 diabetes found decreases in ambulatory diastolic blood pressure with RSG were superior to those with GLB.
Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers
TLDR
A direct effect of TZD treatment on endothelial function and inflammatory biomarkers of arteriosclerosis is suggested, promoting the concept that TZDs, independent of their metabolic action, may exhibit protective effects in the vessel wall.
...
1
2
3
4
5
...